{"filing":{"accession_number":"0001493152-26-032263","cik":"0001712762","ticker":"BIAFW","company_name":"bioAffinity Technologies, Inc.","form":"8-K","filing_date":"2026-07-07","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1712762/000149315226032263/form8-k.htm"},"events":[{"id":16344,"run_id":14598,"accession_number":"0001493152-26-032263","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The filing discloses a press release announcing significant commercial sales acceleration for CyPath® Lung with over 200% year-over-year growth and 30% sequential growth, along with expansion metrics (155% increase in physician offices ordering). While this is a business milestone announcement, it does not fit the specific earnings_release category (which typically reports comprehensive quarterly financial results) but rather represents an operational/commercial milestone. The material growth metrics and market expansion data would affect a reasonable investor's assessment of the company's commercial trajectory and product adoption.","company_name":"bioAffinity Technologies, Inc.","ticker":"BIAFW","filing_date":"2026-07-07","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":14418,"accession_number":"0001493152-26-032263","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The filing discloses a press release announcing significant commercial sales acceleration for CyPath® Lung with over 200% year-over-year growth and 30% sequential growth, along with expansion metrics (155% increase in physician offices ordering). While this is a business milestone announcement, it does not fit the specific earnings_release category (which typically reports comprehensive quarterly financial results) but rather represents an operational/commercial milestone. The material growth metrics and market expansion data would affect a reasonable investor's assessment of the company's commercial trajectory and product adoption.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T19:18:04.100178+00:00","company_name":"bioAffinity Technologies, Inc.","ticker":"BIAFW","filing_date":"2026-07-07"}]}